January 31, 2007

Takeda Pharmaceutical Company Limited

Merger of Three Consolidated Subsidiaries, Daiwa Estate, Shinwa Estate and Takeda Pharmaceutical Real Estate

OSAKA, JAPAN, January 31, 2007 --- Takeda Pharmaceutical Company Limited ("Takeda") announced that its Board of Directors resolved today the merger of three wholly owned subsidiaries which are; Daiwa Estate Company, Ltd. ("Daiwa"), Shinwa EstateCompany, Ltd. ("Shinwa") and Takeda Pharmaceutical Real Estate Company, Ltd. ("Takeda Estate") as follows:

1. Objective of merger

Through this merger, it is expected to establish further efficient business structure of the real estate business within Takeda group.

2. Overview of merger

• (1) Date of merger : Scheduled on April 1, 2007
• (2) Method of merger :Daiwa will be the surviving company, absorbing Shinwa and Takeda Estate which will be dissolved.
• (3) Merger ratio : There are no arrangements with regard to merger ratio as all the three companies are wholly owned subsidiaries of Takeda.

3. Outline of companies as of January 31, 2007

(1)Business Name	Daiwa Estate Company, Ltd.	Shinwa Estate Company, Ltd.	Takeda Pharmaceutical Real Estate Company, Ltd.
(2)Description of Business	Lease, sales and purchase of land and buildings	Lease of buildings	Lease, sales and purchase of land and buildings
(3)Date of Incorporation	June 26, 2006	June 26, 2006	January 11, 1985
(4)Address of Head Office	3-8, Doshomachi 2-chome, Chuo-ku, Osaka	1-2, Doshomachi 3-chome, Chuo-ku, Osaka	1-7, Nihonbashi honcho 2-chome, Chuo-ku, Tokyo
(5)Company Representative	Yasuharu Sugie, President	Yasuharu Sugie, President	Kazuomi Suzuki, President
(6)Paid-in capital	100 million yen	35 million yen	733 million yen
(7)Fiscal Year End	March 31	March 31	March 31
(8)Shares held by Takeda Pharmaceutical Company Limited	100%	100%	100%

4. Outline of new company after merger

• (1) Business Name : Takeda Pharmaceutical Real Estate Company, Ltd.
• (2) Description of Business :Lease, sales and purchase of land and buildings
• (3) Address of Head Office : 1-7, Nihonbashi honcho 2-chome, Chuo-ku, Tokyo
• (4) Company Representative : President, Kazuomi Suzuki
• (5) Paid-in capital : 100 million yen
• (6) Fiscal Year End : March 31

[*]: The surviving company, Daiwa will change its name to Takeda Pharmaceutical Real Estate Company, Ltd. upon merger.

5. Impact on the consolidated financial results of Takeda

Immaterial impact will be incurred from these stock-for-stock exchange, corporate demerger and merger because both Daiwa and Shinwa are consolidated subsidiaries of Takeda.

# # #